相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。One ring is sufficient to inhibit α-synuclein aggregation
Samuel Pena-Diaz et al.
NEURAL REGENERATION RESEARCH (2022)
α-synuclein abnormalities trigger focal tau pathology, spreading to various brain areas in Parkinson disease
Fatemeh Hadi et al.
JOURNAL OF NEUROCHEMISTRY (2021)
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease A Randomized Clinical Trial
Tanya Simuni et al.
JAMA NEUROLOGY (2021)
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Gennaro Pagano et al.
FRONTIERS IN NEUROLOGY (2021)
Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam et al.
LANCET NEUROLOGY (2021)
ALZHEIMER'S DRUG APPROVAL COULD AFFECT OTHER DISEASES
Asher Mullard
NATURE (2021)
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study
Werner Poewe et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Beta2-Adrenoceptor Agonists in Parkinson's Disease and Other Synucleinopathies
Luca Magistrelli et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2020)
beta-adrenoreceptors and the risk of Parkinson's disease
Franziska Hopfner et al.
LANCET NEUROLOGY (2020)
Implications of the Gut Microbiome in Parkinson's Disease
Mohamed Elfil et al.
MOVEMENT DISORDERS (2020)
Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy
Mohammad Shahnawaz et al.
NATURE (2020)
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
Alberto J. Espay et al.
NEUROLOGY (2020)
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies
Anke Van der Perren et al.
ACTA NEUROPATHOLOGICA (2020)
Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates
Marie-Laure Arotcarena et al.
BRAIN (2020)
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations A Nonrandomized, Noncontrolled Trial
Stephen Mullin et al.
JAMA NEUROLOGY (2020)
Parkinson disease and the immune system - associations, mechanisms and therapeutics
Eng-King Tan et al.
NATURE REVIEWS NEUROLOGY (2020)
Current and projected future economic burden of Parkinson's disease in the U.S.
Wenya Yang et al.
NPJ PARKINSONS DISEASE (2020)
Parkinson's disease: etiopathogenesis and treatment
Joseph Jankovic et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PDO1A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc et al.
LANCET NEUROLOGY (2020)
Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease
Joseph Jankovic et al.
MOVEMENT DISORDERS (2020)
A Phase 1 Randomized Trial of Specific Activeα-SynucleinImmunotherapiesPD01AandPD03Ain Multiple System Atrophy
Wassilios G. Meissner et al.
MOVEMENT DISORDERS (2020)
Glymphatic failure as a final common pathway to dementia
Maiken Nedergaard et al.
SCIENCE (2020)
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease
Hardy J. Rideout et al.
FRONTIERS IN NEUROSCIENCE (2020)
Neglected cytotoxic T cell invasion of the brain: how specific for Parkinson's disease?
Glenda Halliday
BRAIN (2020)
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui T. Nimmo et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain
Mita Kuchimanchi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin et al.
JOURNAL OF MOVEMENT DISORDERS (2020)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Alberto J. Espay et al.
NEUROLOGY (2019)
Circuit Mechanisms of Parkinson's Disease
Matthew M. McGregor et al.
NEURON (2019)
Targeting -Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics
Daniel Savitt et al.
DRUGS (2019)
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models
Andreas Weihofen et al.
NEUROBIOLOGY OF DISEASE (2019)
Use of beta 2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease
Franziska Hopfner et al.
NEUROLOGY (2019)
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054
Miroslaw Brys et al.
MOVEMENT DISORDERS (2019)
α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Parvez Alam et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Pathogenesis-targeted therapeutic strategies in Parkinson's disease
Joseph Jankovic
MOVEMENT DISORDERS (2019)
The CNS Immune-Privilege Goes Down the Drain(age)
Simone Brioschi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Immunotherapy in Parkinson's disease: Current status and future directions
Diptaman Chatterjee et al.
NEUROBIOLOGY OF DISEASE (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease
Jessica Y. Vargas et al.
AGEING RESEARCH REVIEWS (2019)
Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
Carroll Rutherford Fields et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Edward Rockenstein et al.
JOURNAL OF NEUROSCIENCE (2018)
Parkinson's disease tremors and serotonin
Joseph Jankovic
BRAIN (2018)
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease
Valentina Caputi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Measurements of auto-antibodies to -synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease
Rizwan S. Akhtar et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity
Anna Wilkaniec et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Martin Kallab et al.
FRONTIERS IN NEUROSCIENCE (2018)
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Nicolas Giguere et al.
FRONTIERS IN NEUROLOGY (2018)
CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Antoine Louveau et al.
NATURE NEUROSCIENCE (2018)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
First-in-human assessment of PRX002, an anti--synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk et al.
MOVEMENT DISORDERS (2017)
Neuropathology of Genetic Synucleinopathies With Parkinsonism: Review of the Literature
Susanne A. Schneider et al.
MOVEMENT DISORDERS (2017)
T cells from patients with Parkinson's disease recognize α-synuclein peptides
David Sulzer et al.
NATURE (2017)
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Yvette C. Wong et al.
NATURE MEDICINE (2017)
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease
Shuchi Mittal et al.
SCIENCE (2017)
Active immunization therapies for Parkinson's disease and multiple system atrophy
Achim Schneeberger et al.
MOVEMENT DISORDERS (2016)
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease
Wolfgang Wrasidlo et al.
BRAIN (2016)
Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease
Goutam Chandra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Review: Sporadic Parkinson's disease: development and distribution of -synuclein pathology
K. Del Tredici et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2016)
Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein
Wei Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model
Alevtina D. Zharikov et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Inflammasomes: mechanism of action, role in disease, and therapeutics
Haitao Guo et al.
NATURE MEDICINE (2015)
FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease
Anke Van der Perren et al.
NEUROBIOLOGY OF AGING (2015)
Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases
Ronald Melki
JOURNAL OF PARKINSONS DISEASE (2015)
The Medical Treatment of Parkinson Disease from James Parkinson to George Cotzias
Stanley Fahn
MOVEMENT DISORDERS (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice
Amanda N. Sacino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation
Luis Fonseca-Ornelas et al.
NATURE COMMUNICATIONS (2014)
Prion-like spreading of pathological α-synuclein in brain
Masami Masuda-Suzukake et al.
BRAIN (2013)
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia
Lisa Fellner et al.
GLIA (2013)
Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin
Wei Shao et al.
NATURE (2013)
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
Kelvin C. Luk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Clinical Progression in Parkinson Disease and the Neurobiology of Axons
Hsiao-Chun Cheng et al.
ANNALS OF NEUROLOGY (2010)
In vivo silencing of alpha-synuclein using naked siRNA
Jada Lewis et al.
MOLECULAR NEURODEGENERATION (2008)
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation
Jia-Yi Li et al.
NATURE MEDICINE (2008)
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
Jeffrey H. Kordower et al.
NATURE MEDICINE (2008)
分享论文
